ストックスクリーナーアプリを入手
16.41
5.30%
0.8522
前日終値:
$15.56
開ける：
$15.86
24時間の取引高:
601.56K
Relative Volume:
0.23
時価総額：
$2.14B
収益：
$745.97M
当期純損益:
$-99.21M
株価収益率:
-21.23
EPS:
-0.7729
ネットキャッシュフロー:
$-5.09M
1週間 パフォーマンス:
+7.16%
1か月 パフォーマンス:
+13.00%
6か月 パフォーマンス:
+43.48%
1年 パフォーマンス:
+184.46%
1日の値動き範囲:
$15.86
$16.46
1週間の範囲:
$15.34
$16.46
52週間の値動き範囲:
$5.63
$16.46
Neogenomics Inc Stock (NEO) Company Profile
Compare NEO vs TMO, DHR, IDXX, NTRA, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
16.41 | 1.71B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
587.31 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.68 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
588.02 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
318.30 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
145.14 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-29 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 開始されました | Guggenheim | Neutral |
| 2025-04-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
NeoGenomics (NEO) Is Down 7.7% After DOJ Settlement On Legacy Agreements – Has The Bull Case Changed? - simplywall.st
NeoGenomics in focus: Earnings test new diagnostic momentum By Investing.com - Investing.com South Africa
NeoGenomics pays $10 million to settle kickback allegations after self-disclosing below-market deals - Peoples Gazette Nigeria
NEO Balance Sheet - TradingKey
NEO|Neogenomics Inc|Price:13.890|Chg%:-0.350 - TradingKey
NEOUSD (NEOUSD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NEO Income Statement - TradingKey
NEOUSD (NEOUSD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For - Yahoo! Finance Canada
NeoGenomics Laboratories to Pay $9.8 Million to Resolve FCA Allegations Relating to Below-Fair-Market-Value Consulting Services - ArentFox Schiff
Neogenomics Inc|Price:13.890|Chg%:-0.350 - TradingKey
NEO|Neogenomics Inc|Price:13.550|Chg%:+0.410 - TradingKey
NeoGenomics Inc. (NEO) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NEO) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics, Inc. Revenue Breakdown – SWB:NG9 - TradingView
NeoGenomics Inc. (NEO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NEO) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics, Inc. (NEO) stock price, news, quote and history - Yahoo Finance UK
NEOGENOMICS INC : BENCHMARK RAISES TARGET PRICE TO $16 FROM $11 - Bitget
NEO Maintained by Benchmark -- Price Target Raised to $16.00 - GuruFocus
Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Raises Target Price to $16 - Moomoo
NeoGenomics Inc. (NEO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NG9) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NG9) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Inc. (NG9) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
NeoGenomics Resolves Federal Healthcare Compliance Probe with $9.8 Million DOJ Settlement - Kalkine Media
NeoGenomics, Inc. Files 8-K/A Amendment Disclosure for July 2026 – NASDAQ: NEO Company Details & Regulatory Update – Minichart - Minichart
Florida lab to pay $9.8 million to settle federal healthcare fraud allegations - Baltimore Sun
NeoGenomics Settles DOJ Investigation Related to Laboratory Collaboration Program - Moomoo
NeoGenomics, Inc. Files 8-K Report on July 20, 2026 – Key Corporate and Financial Disclosure Details - Minichart
NeoGenomics to Pay $9.8M to Resolve Allegations of False Claims Act Violation - Moomoo
NeoGenomics finalizes $9.81M DOJ settlement over voluntary OIG-HHS disclosure - TradingView
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS - Business Wire
NeoGenomics to Pay $9.8 Million to Resolve Allegations of False Claims Act Violation - marketscreener.com
(NEO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Frontier tech research, news & data - MLQ.ai
PRPO vs. NEO: Which cancer diagnostics stock is the better buy? - MSN
NeoGenomics (NEO) Stock Looks Above Fair Value After A 134% Run - Yahoo Finance Singapore
Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch? - Yahoo Finance
NeoGenomics (NEO) Launches PTEN IHC CDx, Does The Valuation Still Look Full? - Sahm
NGMS stock holds its ground after Neogenomics revenue trends improve - Ad-hoc-news.de
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy? - The Globe and Mail
ETFs Investing in NeoGenomics, Inc. Stocks - TradingView
Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO) - The Globe and Mail
Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift? - simplywall.st
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $15.67, Implies 11% Upside - TradingView
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $16 - Moomoo
NeoGenomics Q1 2026 Earnings: Narrow Profit Beats Estimates Amid Market SkepticismRevenue Guidance Range - dars.gov.et
NeoGenomics Inc (NEO) Shares Fall 4.2% -- What GF Score of 72 Te - GuruFocus
NeoGenomics launches $275M convertible notes offering due 2032 - MSN
Press Release: NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 - 富途牛牛
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
0.12%
大文字化:
|
ボリューム (24 時間):